Apollomics, Inc. (APLMW)
Automate Your Wheel Strategy on APLMW
With Tiblio's Option Bot, you can configure your own wheel strategy including APLMW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol APLMW
- Rev/Share 6.2829
- Book/Share -3.9873
- PB -4.8153
- Debt/Equity -0.1692
- CurrentRatio 0.9672
- ROIC -32.2741
- MktCap 21187584.0
- FreeCF/Share -11.5639
- PFCF -1.6611
- PE -0.679
- Debt/Assets 0.0669
- DivYield 0
- ROE -133.8541
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Apollomics Announces Changes to its Board of Directors and Composition of Committees
Published: November 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company's board of directors (“Board”) and composition of committees.
Read More
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
Published: October 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) and request a hearing before a Nasdaq Hearings Panel to review the Staff's delisting determination.
Read More
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
Published: October 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) and request a hearing before a Nasdaq Hearings Panel to review the Staff's delisting determination.
Read More
About Apollomics, Inc. (APLMW)
- IPO Date 2023-03-30
- Website http://www.apollomicsinc.com
- Industry Financial - Conglomerates
- CEO Guo-Liang Yu
- Employees 13